Israeli-American pharmaceutical company NeuroRx is now trading on the Nasdaq index following the completion of a business combination with Big Rock Partners Acquisition Corp, the company announced Monday. The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP.
Follow Israel Hayom on Facebook and Twitter
As a Nasdaq-listed company, NRx will deploy public capital to continue development of two investigational medicines: ZYESAMI, the first FDA Fast Track-designated investigational medicine, being studied in critically-ill patients with COVID-19 induced respiratory failure, and NRX-101 (a combination drug therapy of D-cycloserine and lurasidone), the first investigational medicine to receive FDA Breakthrough Therapy designation for patients with suicidal bipolar depression.
Both ZYESAMI and NRX-101 are now in FDA-approved Phase 3 clinical trials.
"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of 'Bringing Hope to Life,'" said NeuroRx founder and CEO Professor Jonathan Javitt.
